tradingkey.logo
tradingkey.logo
Search

News

Uni-Bio Science Joins Forces with WMU NERC and Ouhai District Government to Build Growth Factor Innovation Ecosystem and Accelerate Regenerative Medicine Strategy Layout

[Hong Kong, December 30th, 2025] Uni-Bio Science Group Limited (“Uni-Bio Science Group”, “Uni-Bio” or “the Group”) is pleased to announce the official signing of a tripartite strategic cooperation agreement in Wenzhou, Zhejiang, with the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University (“WMU NERC”) and the People's Government of Ouhai District, Wenzhou. The parties also explored the subsequent co-establishment of the "Uni-Bio - WMU Joint Innovation Laboratory for Translational Medicine." This collaboration marks a key step for Uni-Bio in deeply integrating with a national-level research platform and a regional industrial ecosystem. Through a synergistic “government-university-enterprise” model, the three parties will focus on the core regenerative medicine field of growth factors to establish an end-to-end innovation system spanning basic research, clinical translation, and industrial application. This represents a milestone for the Group in consolidating its R&D pipeline and accelerating its strategic execution.(Photo: Strategic cooperation signing ceremony group photo)Focusing on Growth Factor Frontiers, Unleashing “1+1>2” Clinical and Market PotentialGrowth factors are key signaling molecules that regulate cell proliferation, migration, and tissue repair, representing some of the most transformative bioactive substances in regenerative medicine. Both EGF (Epidermal Growth Factor) and FGF (Fibroblast Growth Factor) have demonstrated significant efficacy across major indications, including wound healing, ophthalmic diseases, and metabolic disorders, underscoring their substantial market potential. Uni-Bio possesses deep expertise in the EGF field, with its flagship products GeneTime® and GeneSoft® achieving large-scale production and nationwide commercial coverage. Concurrently, under the leadership of Academician Li Xiaokun, the WMU NERC has been a global pioneer in FGF drug R&D, having successfully translated several Class I New Drugs - including Recombinant Human Basic Fibroblast Growth Factor - and has accumulated substantial clinical data and authoritative expert consensus in trauma and metabolic diseases.Building on this foundation, the three parties will initiate collaborative research on combined EGF/FGF therapies for key areas, including burns, dermatology, and ophthalmology. The goal is to unlock powerful therapeutic synergies, develop superior combination products and advance delivery systems, set new treatment benchmarks, and establish a leadership position in shaping this multi-billion Yuan sector.Empowered by Academician Leadership & Platform, Creating a Fast Track from R&D to ProductionThe WMU NERC is an independent legal entity established by Wenzhou Medical University based on the national-level platform, the National Engineering Research Center for Cell Growth Factor Drugs and Protein Preparations. It undertakes downstream functions including engineering technology research and development, transformation of scientific and technological achievements, and technical services. In synergistic collaboration with the National Key Laboratory for Macromolecular Drugs and Large-Scale Preparation, which focuses on upstream basic research, the Center has built a next-generation growth factor drug pipeline targeting multiple systems such as metabolism and dermatology. Through the ongoing research of Academician Li Xiaokun’s team, the Center has achieved internationally leading breakthroughs in key technologies, including long-acting Modification, targeted delivery, and aerosol inhalation.The planned "Uni-Bio – WMU Joint Innovation Laboratory for Translational Medicine" will conduct in-depth research into the synergistic mechanisms of Epidermal Growth Factor (EGF) and Fibroblast Growth Factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair. It aims to develop novel compound formulations and drug delivery systems targeting conditions such as endocrine diseases represented by non-alcoholic steatohepatitis (NASH), respiratory diseases represented by asthma, as well as bone tissue repair. These diseases affect a large global patient population, yet there remains a significant unmet clinical need for innovative therapies. Through this collaboration, it is expected to address treatment gaps in multiple specific indications, further unlocking clinical and commercial value in the broad chronic disease market.The "Government-University-Enterprise " Trinity, Systematically Strengthening Full-Chain CapabilitiesThis collaboration extends beyond technological synergy to ecosystem co-development. The People's Government of Ouhai District, Wenzhou, is a key facilitator and supporter of this strategic cooperation, committed to building a first-class biomedical industry ecosystem. Its core platform, the "China Gene Valley," will provide comprehensive spatial support and specialized policy assistance for the cooperative projects across all stages – from R&D and pilot-scale testing to industrialization.For Uni-Bio, this tripartite cooperation delivers threefold empowerment:R&D Front: Direct access to the National Engineering Research Center’s source innovation and core technologies, elevating the starting point of R&D. Clinical Front: Collaboration with Wenzhou Medical University’s affiliated hospital network to accelerate clinical validation and indication expansion. Commercialization Front: Leveraging the advanced manufacturing capabilities and regional policy benefits of the China Gene Valley to ensure efficient project implementation and facilitate market access.This strategic partnership is a crucial step in the Group's pursuit of its vision "To Be the Global Leader in Regenerative Medicine, Redefining How Science Restores and Extends Human Life" Moving forward, the Group will continue to deepen collaborations with national scientific institutions and local governments, driving the translation of more cutting-edge research into clinical and market value. This will further consolidate and enhance its comprehensive competitiveness and leadership in regenerative medicine.EndAbout Uni-Bio Science:Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001(Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to becoming a global leader in regenerative medicine, redefining how science restores and extends human life.About the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University:The WMU NERC is an independent legal entity established by Wenzhou Medical University based on the national-level platform, the National Engineering Research Center for Cell Growth Factor Drugs and Protein Preparations. It undertakes downstream functions including engineering technology research and development, transformation of scientific and technological achievements, and technical services. Under the leadership of Chinese Academy of Engineering Academician Li Xiaokun, the Center has long been engaged in foundational research and novel drug discovery for cell growth factor drugs, holding a globally leading position. It brings together top-tier scientific teams, undertakes major national science and technology projects, and has successfully developed a series of innovative FGF drugs with independent intellectual property rights. Through synergistic collaboration with the National Key Laboratory for Macromolecular Drugs and Large‑Scale Preparation, the Center forms a complete innovation chain from source discovery and key technological breakthroughs to industrial translation. As the important R&D engine of the China Gene Valley, it continuously promotes the incubation and translation of several original new drug candidates, including a long-acting FGF21 variant.About the People's Government of Ouhai District, Wenzhou:The People's Government of Ouhai District, Wenzhou, is a key facilitator and supporter of this strategic cooperation, committed to building a first-class biomedical industry ecosystem. Its core platform, the "China Gene Valley," will provide comprehensive spatial support and specialized policy assistance for the cooperative projects across all stages – from R&D and pilot-scale testing to industrialization. Through specialized industrial policies, "full-cycle escort" services, and clinical resource coordination, Ouhai District empowers the implementation and growth of innovation projects, serving as a vital driver for regional biomedical industry innovation and development.30/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
EQS
Tue, Dec 30

HEYTEA Partners with POP MART’s Twinkle Twinkle for First Global Simultaneous Launch

Starting December 22, HEYTEA and POP MART’s popular IP Twinkle Twinkle officially launched their global co-branded campaign across HEYTEA stores worldwide. Timed to the Christmas and New Year season, the collaboration is built around the theme “Twinkle Twinkle for Winter.” Centered on the warm and comforting Twinkle Twinkle characters, the campaign introduces a multi-dimensional experience that includes custom character designs, co-branded drinks, themed merchandise, themed stores, and the Inspiration Bus pop-up activation.This marks HEYTEA’s first globally synchronized co-branded launch. Even before the official rollout, the partnership generated strong attention across social platforms. With the campaign spanning Mainland China, Hong Kong SAR and Macao SAR, as well as more than 100 HEYTEA stores across the United States, the United Kingdom, Canada, and other overseas markets, the collaboration brings a shared winter moment to cities around the world.Beyond its festive appeal, the campaign offers a glimpse into HEYTEA’s approach to international markets. While character-led collaborations help create seasonal resonance, HEYTEA’s broader focus lies in building meaningful, locally grounded brand experiences that feel relevant in different cultural contexts.Localized campaigns, shaped by local cultureAcross overseas markets, HEYTEA has consistently used collaborations and pop-up activations as a way to connect with younger audiences and spark cultural conversation. Over the past year, the brand has partnered with names spanning fashion, art, and entertainment, including alexanderwang, Sandy Liang, Wicked, and Yayoi Kusama. Each collaboration is paired with limited products and immersive offline experiences, encouraging consumers to engage, explore, and share.Rather than applying a single formula across regions, HEYTEA selects creative partners with strong local or cultural relevance, develops visually distinctive concepts, and designs in-store experiences that naturally translate into social moments. This approach allows the brand to build local presence while maintaining a coherent global identity rooted in inspiration and creativity.Product creativity as a shared languageProduct creation remains central to how HEYTEA expresses its brand globally. As the originator of “new-style tea,” the brand views innovation as a way to continuously reinterpret tea culture for contemporary consumers, both in China and overseas.Internationally, HEYTEA has introduced more than 20 localized drinks designed to reflect regional taste preferences while staying true to the brand’s emphasis on natural ingredients and modern tea aesthetics. Examples include Cloud Coconut Blue, Cloud Longjing Tea Latte, and Ocean’s Glow, which incorporate lighter flavor profiles, lower sugar options, and plant-forward elements to better align with local expectations.This philosophy is reflected in the Twinkle Twinkle collaboration itself. Alongside HEYTEA’s globally available classics, the campaign introduces two exclusive drinks, Tiramisu Milk Tea and Tiramisu Rich Chocolate, marking the brand’s first globally synchronized seasonal product release. For HEYTEA, seasonal storytelling is less about promotion and more about creating moments of comfort, warmth, and shared experience across markets.The U.S. as a key stage for cultural connectionThe United States continues to play an important role in HEYTEA’s overseas presence. Since opening its first U.S. store at the end of 2023, the brand has expanded into cities including New York, Los Angeles, the San Francisco Bay Area, Houston, Seattle, and Boston. HEYTEA now operates 36 stores across the country.For HEYTEA, the appeal of the U.S. lies not only in market scale, but also in its openness to new tastes and ideas. The brand sees tea as a cultural medium, one that can create connection through shared sensory experiences. This perspective has shaped both store design and product development, encouraging exploration rather than simple adaptation.In New York’s Times Square, HEYTEA opened its overseas flagship TEA LAB store, a space designed to reinterpret Chinese tea culture through an inspiration-driven lens. Featuring exclusive drinks and a carefully curated environment, the flagship serves as a creative showcase for how tea can be experienced in a modern, global city.Supporting experiences behind the scenesAs HEYTEA expands internationally, it continues to refine the systems that support consistent experiences across markets. The brand has extended its HEYTEA GO digital platform overseas and introduced a self-operated delivery model in the U.S., helping ensure a more seamless and reliable customer journey. These behind-the-scenes capabilities allow HEYTEA to focus on what consumers see and feel, while maintaining quality and coherence across regions.About HEYTEAFounded in 2012 in Jiangmen, Guangdong, China, HEYTEA is widely recognized as the originator of new-style tea beverages. The brand created the world’s first cheese tea using real tea and real milk, setting a new standard for the industry. HEYTEA is committed to using real ingredients, including real tea, real milk, real fruit, and real sugar, while continuously reimagining tea culture through products and experiences that resonate with young consumers. Today, HEYTEA operates around 4,000 stores worldwide, including more than 100 overseas locations across Asia, North America, Europe, and Oceania.Company Name: HEYTEAMedia Contact: Matthew ZhouEmail(邮箱): zhouhaoge@heytea.comWebsite(官网): www.heytea.com30/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
EQS
Tue, Dec 30
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.